Evidence map›Paper›PMID 26065911›Full record

ArticleScientific reports2015

Dietary ω3 fatty acid exerts anti-allergic effect through the conversion to 17,18-epoxyeicosatetraenoic acid in the gut.

Jun Kunisawa, Makoto Arita, Takahiro Hayasaka, Takashi Harada, Ryo Iwamoto, Risa Nagasawa, Shiori Shikata, Takahiro Nagatake, Hidehiko Suzuki, Eri Hashimoto and 5 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers.

0numbers the graph read from it
0cells of the map it votes in
52citing papers in PubMed
8.1field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

52 citing papers in PubMed, 118 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Aflatoxin BEcotoxicology and environmental safety · 2023
    Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. The metabolic plasticity of B cells.Frontiers in molecular biosciences · 2022
    Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 5 institutions in 1 country.

Jun Kunisawa1] Laboratory of Vaccine Materials, National Institute of Biomedical Innovation, Health and Nutrition, Osaka 567-0085, Japan [2] Division of Mucosal Immunology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo 108-8639, Japan [3] International Research and Development Center for Mucosal Vaccines, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan [4] Core Research for Evolutional Science and Technology (CREST), Japan Science and Technology Agency, Tokyo 102-0075, Japan [5] Kobe University Graduate School of Medicine, Hyogo 650-0017, Japan [6] Graduate School of Medicine, Graduate School of Pharmaceutical Sciences, and Graduate School of Dentistry, Osaka University, Osaka 565-0871, Japan [7] Graduate School of Pharmaceutical Sciences, Osaka University, Osaka 565-0871, Japan [8] Graduate School of Dentistry, Osaka University, Osaka 565-0871, Japan.
Makoto Arita1] Laboratory for Metabolomics, RIKEN Center for Integrative Medical Sciences, Kanagawa 230-0045, Japan [2] Graduate School of Medical Life Science, Yokohama City University, Kanagawa 230-0045, Japan [3] Departments of Health Chemistry, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo 113-0033, Japan [4] Precursory Research for Embryonic Science and Technology (PRESTO), Japan Science and Technology Agency (JST), Tokyo 102-8666, Japan.
Takahiro HayasakaDepartment of Cell Biology and Anatomy, Hamamatsu University School of Medicine, Shizuoka 431-3192, Japan.
Takashi HaradaDepartment of Cell Biology and Anatomy, Hamamatsu University School of Medicine, Shizuoka 431-3192, Japan.
Ryo IwamotoDepartments of Health Chemistry, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo 113-0033, Japan.
Risa Nagasawa1] Laboratory of Vaccine Materials, National Institute of Biomedical Innovation, Health and Nutrition, Osaka 567-0085, Japan [2] Division of Mucosal Immunology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo 108-8639, Japan.
Shiori Shikata1] Laboratory of Vaccine Materials, National Institute of Biomedical Innovation, Health and Nutrition, Osaka 567-0085, Japan [2] Division of Mucosal Immunology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo 108-8639, Japan.
Takahiro NagatakeLaboratory of Vaccine Materials, National Institute of Biomedical Innovation, Health and Nutrition, Osaka 567-0085, Japan.
Hidehiko SuzukiLaboratory of Vaccine Materials, National Institute of Biomedical Innovation, Health and Nutrition, Osaka 567-0085, Japan.
Eri Hashimoto1] Laboratory of Vaccine Materials, National Institute of Biomedical Innovation, Health and Nutrition, Osaka 567-0085, Japan [2] Division of Mucosal Immunology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo 108-8639, Japan.
Yosuke Kurashima1] Laboratory of Vaccine Materials, National Institute of Biomedical Innovation, Health and Nutrition, Osaka 567-0085, Japan [2] Division of Mucosal Immunology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo 108-8639, Japan.
Yuji SuzukiDivision of Mucosal Immunology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo 108-8639, Japan.
Hiroyuki Arai1] Core Research for Evolutional Science and Technology (CREST), Japan Science and Technology Agency, Tokyo 102-0075, Japan [2] Departments of Health Chemistry, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo 113-0033, Japan.
Mitsutoshi Setou1] Department of Cell Biology and Anatomy, Hamamatsu University School of Medicine, Shizuoka 431-3192, Japan [2] The Institute of Medical Science, The University of Tokyo, Tokyo 108-8639, Japan.
Hiroshi Kiyono1] Division of Mucosal Immunology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo 108-8639, Japan [2] International Research and Development Center for Mucosal Vaccines, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan [3] Core Research for Evolutional Science and Technology (CREST), Japan Science and Technology Agency, Tokyo 102-0075, Japan [4] Department of Medical Genome Science, Graduate School of Frontier Science, The University of Tokyo, Chiba 277-8562, Japan [5] Department of Medical Genome Science, Graduate School of Frontier Science, The University of Tokyo, Chiba 277-8562, Japan [6] Graduate School of Medicine, The University of Tokyo, Tokyo 113-0033, Japan [7] Graduate School of Medicine, The University of Tokyo, Tokyo 113-0033, Japan.
National Institute of Biomedical Innovation, Health and Nutrition · JPThe University of Tokyo · JPHamamatsu University School of Medicine · JPJapan Science and Technology Agency · JPRIKEN Center for Integrative Medical Sciences · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

ω3 polyunsaturated fatty acids (PUFAs) have anti-allergic and anti-inflammatory properties, but the immune-metabolic progression from dietary oil remains to be investigated. Here we identified 17,18-epoxyeicostetraenoic acid (17,18-EpETE) as an anti-allergic metabolite generated in the gut from dietary ω3 α-linolenic acid (ALA). Biochemical and imaging mass spectrometry analyses revealed increased ALA and its metabolites, especially eicosapentaenoic acid (EPA), in the intestines of mice receiving ALA-rich linseed oil (Lin-mice). In murine food allergy model, the decreased incidence of allergic diarrhea in Lin-mice was due to impairment of mast cell degranulation without affecting allergen-specific serum IgE. Liquid chromatography-tandem mass spectrometry-based mediator lipidomics identified 17,18-EpETE as a major ω3 EPA-derived metabolite generated from dietary ALA in the gut, and 17,18-EpETE exhibits anti-allergic function when administered in vivo. These findings suggest that metabolizing dietary ω3 PUFAs generates 17,18-EpETE, which is an endogenous anti-allergic metabolite and potentially is a therapeutic target to control intestinal allergies.

Indexed as

Fatty Acids, Omega-3AnimalsDisease Models, AnimalFemaleFood HypersensitivityIntestinal MucosaIntestinesLinseed OilMiceMice, Inbred BALB CFatty Acids, Omega-3Linseed Oil

Identifiers

PMID26065911
PMCPMC4464255
OpenAlexW657518852

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.